FDA
-
-
-
-
-
-
-
Stifel on Insmed (INSM): UTHR trial meeting endpoint removes overhang for INSM
-
-
-
-
-
-
-
Insmed reports strong BRINSUPRI launch with $172.7 million in revenue
-
-
-
-
-
-
-
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $148 at Jefferies
-
-
-
-
-
-
-
Insmed Announces Proposed $650 Million Public Offering of Common Stock
-
-
-
-
-
-
-
Insmed (INSM): New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
-
-
-
-
-
-
-
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
-
328,440 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

